Xultophy 100/3.6 Injection, Solution
Product Images NDC 0169-2911

Product Visual Gallery

This gallery contains 30 technical images submitted to the FDA as part of the official labeling for Xultophy 100/3.6 (NDC 0169-2911). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Novo Nordisk, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Export 00

An instructional illustration showing a hand holding a Xultophy 100/3.6 injection pen with the cap being removed by pulling it upward. A close-up inset shows the pen cap being pulled off the pen body, indicating the first step in preparing the injection pen for use.*

FDA Label Image

Figure 1: Structural Formula Of Insulin Degludec (Image 01)

Chemical structure diagram of insulin degludec, part of the active ingredients in Xultophy 100/3.6 injection solution. The diagram depicts amino acid sequences and side chain molecular components characteristic of this peptide hormone.*

FDA Label Image

Figure 2: Structural Formula Of Liraglutide (Image 02)

Chemical structure diagram of liraglutide, showing the sequence of amino acids and molecular configuration. The diagram illustrates the peptide chain with labeled amino acid residues and a fatty acid side chain characteristic of liraglutide.*

FDA Label Image

Figure 3: Graph For Study A (Image 03)

Xultophy 100/3.6 injection, solution in a clear glass vial with a white and blue label. The label shows the product name Xultophy 100/3.6, active ingredients insulin degludec and liraglutide, strength 100 iU/mL and 3.6 mg/mL, and the Novo Nordisk logo. The vial contains a clear liquid injectable solution for subcutaneous use.*

FDA Label Image

Figure A Picture Of The Pen And Needle Components (Image 04)

Illustration showing the components of a NovoFine needle assembly including the outer needle cap, inner needle cap, needle, and paper tab. The image visually separates each part to detail the needle's protective covers and packaging element.*

FDA Label Image

Figure L 200 Units Left (Image 05)

An instructional diagram labeled 'Figure L' depicting a red and transparent insulin injection pen indicating an example dose with approximately 200 units remaining inside the cartridge. The pen includes volume markings from 0 to 65 mL on the side.*

FDA Label Image

Image Of The Carton 5 X 3ml (Image 06)

Packaging label for Xultophy 100/3.6 injection, solution containing insulin degludec and liraglutide at strengths of 100 units/mL and 3.6 mg/mL. The label shows a 5x3 mL prefilled pen package, intended for subcutaneous use, manufactured by Novo Nordisk. The label also includes dosing warnings, storage instructions, and images of the prefilled pen device.*

FDA Label Image

Priming Symbol (Image 07)

An illustrated diagram of the Xultophy 100/3.6 pen injection showing labeled parts including pen cap, pen scale, pen window, dose counter, dose pointer, dose selector, dose button, and priming symbol. The pen label displays the product name Xultophy 100/3.6 with active ingredients insulin degludec and liraglutide.*

FDA Label Image

Qr Code For Additional Info (Image 08)

FDA Label Image

Cover Page (Image 09)

Label displaying Xultophy 100/3.6, an injection solution with 100 units/mL insulin degludec and 3.6 mg/mL liraglutide for subcutaneous use. The image includes a depiction of the pen injector device in pink and blue colors. Labeler Novo Nordisk is indicated at the bottom.*

FDA Label Image

Figure B (Image 10)

Illustration showing a close-up of hands handling an injection pen or device, with one hand holding the device and the other hand pulling or sliding a component, indicated by an arrow suggesting movement or removal.*

FDA Label Image

Figure C (Image 11)

An instructional illustration showing a hand holding a pen-like injection device with the needle cap being removed. The image emphasizes preparing the insulin pen for subcutaneous injection, specifically for Xultophy 100/3.6 containing insulin degludec and liraglutide.*

FDA Label Image

Figure D (Image 12)

Instructional illustration showing the steps to prepare the injection device for Xultophy 100/3.6, highlighting the removal of a cap or cover by pulling it off with the thumb and finger before use.*

FDA Label Image

Figure E (Image 13)

Instructional illustration showing the use of NovoFine and NovoTwist needles for subcutaneous injection. The image depicts positioning the needle cap with rotational arrows indicating removal or attachment steps.*

FDA Label Image

Figure F (Image 14)

An instructional illustration showing the removal of needle caps from NovoFine and NovoTwist needles. The image depicts hands pulling off the protective caps from each needle type, indicated by arrows pointing away from the needles.*

FDA Label Image

Figure G (Image 15)

An instructional illustration showing the process of removing needle caps from a NovoFine and NovoTwist injection device, indicating the steps with arrows.*

FDA Label Image

Figure H (Priming)

An instructional illustration showing hands holding a Xultophy 100/3.6 injection pen with an arrow indicating rotation to select the priming symbol. The inset shows the priming symbol highlighted on the pen's display, indicating the pen is set for priming before injection.*

FDA Label Image

Figure I (Image 17)

An instructional diagram illustrating how to hold and handle a dose of Xultophy 100/3.6 injection solution. The image focuses on one hand holding the pen device with an indication that the pen should be shaken or vibrated gently before use, as suggested by the wavy motion lines next to the pen.*

FDA Label Image

Figure K (Turn dose selector)

Instructional diagram illustrating dose selection on the Xultophy 100/3.6 injection pen. The image shows hands adjusting the dose dial, with examples of the dose display window indicating 16 units and 27 units selected for subcutaneous injection.*

FDA Label Image

Image 20

Chemical structure diagrams of insulin degludec and liraglutide, the active ingredients in Xultophy 100/3.6 injection solution. The image displays the molecular formulas representing both compounds, indicating their chemical composition.*

FDA Label Image

Figure M (Image 21)

An instructional diagram showing recommended subcutaneous injection sites on a human figure viewed from front and back. Highlighted areas include the abdomen and upper thighs on the front, and the upper buttocks on the back.*

FDA Label Image

Figure N (Image 22)

An instructional illustration showing a hand holding a pen injector device vertically with the thumb pressing down on the top, highlighting the action of injecting or activating the device. This diagram appears to be part of instructions for use of the Xultophy 100/3.6 injection, solution pen injector.*

FDA Label Image

Figure O (Press dose button)

Instructional illustration showing a hand holding a prefilled pen injecting Xultophy 100/3.6 subcutaneously, with an arrow indicating the direction of injection and a dose dial set to zero on the device.*

FDA Label Image

Figure P (Image 24)

An instructional illustration showing a hand holding a pen-type injection device, with a speech bubble indicating to count slowly from 1 to 6. The image is related to the administration technique for Xultophy 100/3.6, a subcutaneous injection solution of insulin degludec and liraglutide by Novo Nordisk.*

FDA Label Image

Figure Q (Image 25)

Instructional diagram depicting a subcutaneous injection technique. The image shows an injection pen needle positioned above the skin with an upward blue arrow indicating the direction to lift or pinch the skin before injection.*

FDA Label Image

Figure R (Image 26)

Illustration diagram demonstrating the use of NovoFine and NovoTwist pen needles. The image shows steps for attaching and removing the pen needles by twisting them onto and off the injector pen, indicating the direction of rotation with arrows.*

FDA Label Image

Figure S (Image 27)

An instructional diagram showing the removal of a protective cap from the tip of an injection pen or syringe. The image uses arrows to indicate the direction in which the cap should be pulled away before proceeding with injection preparation or use.*

FDA Label Image

Figure T (Image 28)

An instructional illustration showing hands aligning and connecting two parts of a pen device, indicated by an arrow pointing towards the connection site. The image depicts a step in assembling or preparing an injection pen, relevant to subcutaneous injection products like Xultophy 100/3.6.*

FDA Label Image

Image 30

A line graph displaying HbA1c (%) values over weeks for two treatments: IDegLira and Liraglutide. The x-axis represents time in weeks, ranging from 0 to 26 weeks plus multiple imputation (MI). The y-axis shows HbA1c percent values from about 6.0% to 9.0%. IDegLira data is shown with a solid line and black circles, indicating a decline in HbA1c over time. Liraglutide data is represented by a dotted line and gray squares, with relatively stable HbA1c values. The graph depicts observed values for subjects at scheduled visits and estimates based on multiple imputation.*

FDA Label Image

Image 31

An instructional diagram illustrating four components of a NovoTwist injection pen needle: the outer needle cap, inner needle cap, needle, and paper tab. Each part is labeled and shown separately in a row, providing a visual guide for assembly or use.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.